



ICD-10 & Other Coding Revisions to Laboratory National Coverage Determinations: October 2023 Update

Related CR Release Date: June 29, 2023

MLN Matters Number: MM13269

Effective Date: October 1, 2023

Related Change Request (CR) Number: [CR 13269](#)

Implementation Date: October 2, 2023

Related CR Transmittal Number: R12113CP

Related CR Title: Changes to the Laboratory National Coverage Determination (NCD) Edit Software for October 2023

Affected Providers

- Physicians
- Suppliers
- Other providers billing Medicare Administrative Contractors (MACs) for services they provide to Medicare patients

Action Needed

Make sure your billing staffs are aware of these changes:

- Newly available codes
- Recent coding changes
- How to find NCD coding information

Background

CR 13269 is a maintenance update of ICD-10 conversions and other coding updates specific to NCDs. These NCD coding changes are the result of newly available codes, coding revisions to NCDs released separately, or coding feedback received.

The translations from ICD-9 to ICD-10 aren't consistent one-to-one matches, nor are all ICD-10 codes appearing in a complete General Equivalence Mappings (GEMs) mapping guide or other mapping guides appropriate when reviewed against individual NCD policies.

Relevant NCD coding changes in CR 13269 include:

- NCD 190.12 – Medicare for the Urine Culture, Bacterial

- NCD 190.13 – Human Immunodeficiency Virus (HIV) Testing (Prognosis Including Monitoring)
- NCD 190.14 – Human Immunodeficiency Virus (HIV) Testing (Diagnosis)
- NCD 190.15 – Blood Counts
- NCD 190.16 – Medicare for the Partial Thromboplastin Time (PTT)
- NCD 190.17 – Prothrombin Time (PT)
- NCD 190.18 – Serum Iron Studies
- NCD 190.19 – Collagen Crosslinks, Any Method
- NCD 190.20A – Blood Glucose Testing
- NCD 190.20B – Blood Glucose Testing
- NCD 190.21 – Glycated Hemoglobin/Glycated Protein
- NCD 190.22 – Thyroid Testing
- NCD 190.23A – Lipids Testing
- NCD 190.23B – Lipids Testing
- NCD 190.24 – Digoxin Therapeutic Drug Assay
- NCD 190.25 – Alpha-fetoprotein
- NCD 190.26 – Carcinoembryonic Antigen
- NCD 190.27 – Human Chorionic Gonadotropin
- NCD 190.28 – Tumor Antigen by Immunoassay CA 125
- NCD 190.29 – Tumor Antigen by Immunoassay CA 15-3/CA 27.29
- NCD 190.30 – Tumor Antigen by Immunoassay CA 19-9
- NCD 190.31 – Prostate Specific Antigen
- NCD 190.32 – Gamma Glutamyl Transferase
- NCD 190.33 – Hepatitis Panel/Acute Hepatitis Panel
- NCD 190.34 – Fecal Occult Blood Test

[Previous NCD coding changes](#) are available. Also, see the [NCD spreadsheets](#) for CR 13269.

CMS isn't including any policy changes in this ICD-10 quarterly update. We cover NCD policy changes using the current, longstanding NCD process.

Your MAC will adjust any claims processed in error associated with CR 13269 that you bring to their attention.

More Information

We issued CR 13269 to your MAC as the official instruction for this change.

For more information, [find your MAC's website](#).

Document History

Date of Change	Description
June 30, 2023	Initial article released.

View the [Medicare Learning Network® Content Disclaimer and Department of Health & Human Services Disclosure](#).

The Medicare Learning Network®, MLN Connects®, and MLN Matters® are registered trademarks of the U.S. Department of Health & Human Services (HHS).